Danaher (NYSE:DHR)‘s stock had its “buy” rating reiterated by stock analysts at Needham & Company LLC in a research report issued to clients and investors on Friday, Marketbeat reports. They currently have a $155.00 target price on the conglomerate’s stock, up from their previous target price of $142.00. Needham & Company LLC’s target price would suggest a potential upside of 9.46% from the company’s previous close.
DHR has been the topic of several other research reports. Wolfe Research assumed coverage on Waters in a report on Thursday, May 30th. They set an “underperform” rating on the stock. Janney Montgomery Scott increased their price target on Danaher from $136.00 to $174.00 and gave the company a “buy” rating in a report on Wednesday, April 17th. Piper Jaffray Companies upgraded Post from a “neutral” rating to an “overweight” rating and increased their price target for the company from $106.00 to $130.00 in a report on Thursday. Finally, Zacks Investment Research lowered GALP ENERGIA SG/ADR from a “hold” rating to a “sell” rating in a research note on Monday, May 6th. Three analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $139.08.
NYSE:DHR opened at $141.61 on Friday. The firm’s fifty day moving average is $140.27. Danaher has a fifty-two week low of $94.59 and a fifty-two week high of $145.50. The stock has a market cap of $101.38 billion, a price-to-earnings ratio of 31.33, a PEG ratio of 2.56 and a beta of 0.96. The company has a quick ratio of 1.74, a current ratio of 2.18 and a debt-to-equity ratio of 0.32.
Danaher (NYSE:DHR) last released its quarterly earnings results on Thursday, July 18th. The conglomerate reported $1.19 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.15 by $0.04. Danaher had a return on equity of 11.73% and a net margin of 12.22%. The company had revenue of $5.16 billion for the quarter, compared to analyst estimates of $5.09 billion. During the same quarter in the prior year, the firm posted $1.15 EPS. Danaher’s quarterly revenue was up 3.5% compared to the same quarter last year. As a group, analysts anticipate that Danaher will post 4.77 earnings per share for the current fiscal year.
In other news, SVP William King sold 12,950 shares of the stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $129.92, for a total transaction of $1,682,464.00. Following the transaction, the senior vice president now owns 29,070 shares of the company’s stock, valued at approximately $3,776,774.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Angela S. Lalor sold 3,091 shares of the stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $132.23, for a total value of $408,722.93. Following the transaction, the senior vice president now directly owns 38,515 shares in the company, valued at approximately $5,092,838.45. The disclosure for this sale can be found here. In the last quarter, insiders sold 453,448 shares of company stock worth $59,724,640. Insiders own 11.40% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. CX Institutional grew its position in shares of Danaher by 188.7% during the 1st quarter. CX Institutional now owns 205 shares of the conglomerate’s stock worth $27,000 after buying an additional 134 shares in the last quarter. Executive Wealth Management LLC bought a new position in shares of Danaher during the 4th quarter worth $39,000. Lenox Wealth Management Inc. bought a new position in shares of Danaher during the 1st quarter worth $40,000. Sontag Advisory LLC bought a new position in shares of Danaher during the 4th quarter worth $47,000. Finally, Clarfeld Financial Advisors LLC bought a new position in shares of Danaher during the 4th quarter worth $50,000. 78.82% of the stock is currently owned by institutional investors and hedge funds.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
Further Reading: Cost of Capital
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.